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The incidence of bone metastases (BM) in advanced non-small-
cell lung cancer (NSCLC) patients is estimated to range from 30% to
40% [1,2]. The presence of BM often results in pathologic re-
modeling of the affected bone compartment, making affected
bones vulnerable to skeletal related events (SREs). SREs include
pathologic fractures, spinal cord compression, requirement for
radiation, surgery to bone and hypercalcemia, all reducing quality
of life and worsening prognosis [3]. BM is a poor prognostic sur-
vival factor [4]. Therefore, early diagnosis and adequate treatment
of BM is critically important issues of the clinical management of
NSCLC patients.
To detect BM in NSCLC patients, bone scintigraphy combined
with plain radiographs, computerized tomography (CT) and mag-
netic resonance imaging (MRI) is recommended. But routine
radiography only gives deﬁnite diagnosis when the bone is already
substantially damaged by the tumor. Although scintigraphy is
more sensitive, its speciﬁcity is not satisfactory due to pseudo-
positive values caused by inﬂammation and traumatic fracture.
Any abnormal scintigraphic ﬁndings should always be veriﬁed by
radiographic ones [5]. Bone scintigraphy is also a more expensive,
invasive, time-consuming, and exposes cancer patients to irra-
diation, limiting its use for monitoring purposes.
Since BM impairs the balance between bone formation and
bone resorption, altered bone remodeling activities can be as-
sessed directly by measuring the components of affected bonex.doi.org/10.1016/j.jbo.2015.09.003
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hors.cells or indirectly by analyzing metabolic products released from
the bone matrix by changed rates of bone formation or resorption.
Numerous new analytical tools for bone turnover markers (BTMs)
have improved the diagnosis of BM. These BTMs have been re-
commended as helpful tools for assessing BM [6]. Collectively,
there seem to be a diversity of ﬁndings depending on cancer type
and the type of BTMs used. Previous researches had explored the
applications of BTMs in NSCLC patients [7–19], nevertheless, as to
the optimal markers and their proper application in BM screening,
there hasn't been a consistent agreement, which greatly hampered
the BTMs usage in clinical practice.
Therefore, we (1) measured serum markers of bone formation
and bone resorption as noninvasive analytes of bone turnover in
NSCLC patients with or without BM, (2) assessed the diagnostic
accuracy of these BTMs as potential indicators of BM in NSCLC
patients, combined diagnostic effectiveness of BTMs and (3)
evaluated with univariate and multivariate analysis of the useful-
ness of BTMs to make a prognosis in NSCLC patients with BM. We
selected bone-speciﬁc alkaline phosphatase (BALP), N-terminal
midfragment of osteocalcin (N-MID) and aminoterminal propep-
tide of type I collagen (PINP) as bone formation markers, β-cross-
linked carboxyterminal telopeptide of type I collagen (β-CTx) as
bone resorption markers.2. Materials and methods
2.1. Patients and samples
2.1.1. Patients
Our retrospective study included 414 newly diagnosed NSCLC
patients that were investigated and treated in the department of
internal oncology of the Sixth People's Hospital, Shanghai Jiao
Tong University between January 2010 and December 2013. Allicle under the CC BY-NC-ND license
Table 1
Demographic and Clinicopathologic Characteristics of the Study Groups.
Characteristics Control Group Group A Group B
Sex
Female 84 89 95
Male 95 104 126
Age 57711 5579 59710
Tumor stage:
T1 — 23 —
T2 — 37 —
T3 — 47 —
T4 — 86 221
Pathologic type
Adenocarcinoma — 91 120
Squamous cell carcinoma — 28 29
Adenosquamous carcinoma — 10 8
Poor differentiated carcinoma — 50 53
Alveolar cell carcinoma — 6 5
Large cell carcinoma — 8 6
Therapy
Operation — 88 2
Chemotherapy — 107 178
Target therapy — 44 64
General condition
ECOG:0-1 179 159 182
ECOG:2 0 34 39
Z. Wang et al. / Journal of Bone Oncology 4 (2015) 85–9186participants signed approved written consents; the study was
done in accordance with the Helsinki Declaration II and Standards
of Good Clinical Practice. The Local Ethical Committee has ap-
proved the study protocol.
The study consisted of three groups: Group A included 193
NSCLC patients without BM at diagnosis, Group B included 221
NSCLC patients with BM at diagnosis, and Group control included
179 healthy volunteers. The diagnosis of all NSCLC patients was
conﬁrmed by histological or cytological examination of specimens
taken from bronchoscopy or by CT-guided ﬁne needle biopsy.
Cancer stage was assigned according to the TNM system. All pa-
tients underwent bone scanning using a radionuclide (Techne-
tium-99m) scintigraphy together with plain radiographs, CT and/
or MRI to verify and quantify the presence of BM. In special cases,
affected bone lesions by CT-guided ﬁne needle biopsy were used
to diagnose BM.
2.1.2. Patients' evaluation
Baseline evaluation included clinical assessment, bone survey,
evaluation for extraskeletal disease and serum BTMs
determination.
Clinical evaluation included assessment of performance status
according to the World Health Organization (WHO) criteria. SREs
at diagnosis were recorded, patients were followed up for survival
every 3 months and SREs in follow-up were also recorded.
Bone survey included bone scintigraphy and plain radiological,
as well as CT or MRI when necessary. Patients were initially clas-
siﬁed according to the type and bulk of BM, based on the ﬁndings
of the bone survey. BM type was characterised as lytic, blastic or
mixed. The bulk of BM concerned the number of sites involved and
was graded as previously proposed by Soloway [20]. Brieﬂy, So-
loway 0 refers to patients without BM; Soloway 1 refers to patients
with o6 BM; Soloway 2 refers to patients with o20 BM; Soloway
3 refers to patients with 420 but less than a “super scan”; Solo-
way 4 refers to patients with “super scan” that is deﬁned by a
475% involvement of the ribs, vertebrae, and pelvic bones.
2.1.3. Samples
Blood samples were collected in plastic tubes between 07:30
and 09:00 a.m., stored in ice and centrifuged at 2000g for 15 min,
at 4 °C, within 2 h from venipuncture. Blood samples were col-
lected before the administration of any anticancer treatment after
initial diagnosis.
Bone Formation Markers. BALP was determined by the Tan-
dem-MP Ostase Immunoenzymetric Assay (Beckman Colter, Full-
erton, CA), which speciﬁcally quantiﬁes BALP with low im-
munoreactivity for the liver/kidney isoforms [21]. N-MID (N-MID-
Osteocalcin Assay, Roche) and PINP (Total PINP-Assay, Roche) were
measured on the Elecsys 2010 analyzer (Roche). The PINP assay is
a new electrochemiluminescent assay that detects both tri- and
monomeric PINP forms.
Bone Resorption Markers. β-CTX was determined by the β-
CrossLaps Assay (Roche) on the Elecsys 2010 analyzer [22].
2.2. Statistical analysis
Statistical calculations were performed with SPSSs 13 for
Windows™ and GraphPads Prisms 4.03. All results are expressed
as mean7SD. We used the nonparametric Kruskal–Wallis ANOVA
with Dunn's post test, the Mann–Whitney U test, Spearman's rank
correlation coefﬁcients and the Kolmogorov–Smirnov distribution
ﬁtting procedure. Diagnostic accuracy was evaluated by Receiver-
operating characteristic (ROC) curve analysis. For the combined
diagnostic effectiveness of BTMs, the probability was ﬁtted by lo-
gistic regression model and then analysed by ROC curves. The
Kaplan–Meier product limit method was used to determinesurvival probability in subgroups. Univariate and multivariate
analysis of risk factors predicting NSCLC speciﬁc death was per-
formed using the Cox proportional hazards regression model.
Differences and associations were considered statistically sig-
niﬁcant if po0.05.3. Results
3.1. Demographics characteristics
221 patients suffered from clinically manifest BM and 33.5%
had more than seven BM lesions. In group A, 1 or more metastases
in the lung, liver, and other sites (excluding brain) were present in
49.1% patients, while in group B the number is 44.6%. The majority
of the patients in both groups received chemotherapy during the
study (55.4% in the group A and 80.5% in the group B), and 22.8% in
the group A and 29.0% in the group B received target therapy.
There were no age or sex difference among the subgroups. For
further clinicopathologic data see Table 1 and 2.
3.2. Serum BTMs in the study groups
Fig. 1 shows the scatter plots and medians of all BTMs among
the subgroups. Since all markers showed a Gaussian distribution
using the Kolmogorov–Smirnov test, we calculated the parametric
upper 95% reference limits. Brieﬂy, ANOVA analysis showed bone
formation BALP, PINP, N-MID and bone resorption β-CTx values
were higher in BM patients than in the control group (po0.05)
and in patients without BM (po0.05), but no difference was found
between the control group and the group without BM (p40.05).
For further data see Fig. 1.
3.3. BTMs as diagnostic Indicators of BM
3.3.1. ROC analyses between NSCLC patients with or without BM
ROC analyses were performed to characterize the diagnostic
usefulness of the BTMs, which is to differentiate NSCLC patients
with or without BM (Fig. 2 and Table 3). Both bone formation and
resorption markers were helpful in this respect. ROC curves were
drawn according to the markers based on true-postive ratio
Table 2
Clinic Characteristics of Group B.
Characteristics Number
The extent of BM
Soloway 1 147
Soloway 2 65
Soloway 3-4 9
Character of BM
Lytic 153
Blastic 13
Mixed 55
Pain level
Mild pain (VAS score:0-3) 56
Moderate pain (VAS score:4-
6)
141
Severe pain (VAS score:7-10) 24
With visceral metastases
Yes 94
No 127
SREs at diagnosis
Yes 24
No 197
SREs in follow-up
Yes 84
No 137
Fig. 2. ROC curves for BTMs to discriminate NSCLC patients with and without BM.
Area under curve for BALP was 0.78770.056, for PINP was 0.68870.064, for
N-MID was 0.78270.054, and for β-CTx was 0.66270.067.
Table 3
Sensitivity, speciﬁcity, diagnostic efﬁciency of BTMs to discriminate NSCLC patients
with and without BM.
Area 95%CI Cut-off SE% SP%
BALP (μg/L) 0.787 0.731–0.843 16.96 53.7 80.8
PINP (ng/mL) 0.688 0.623–0.752 52.75 60.2 85.0
N-MID (ng/mL) 0.782 0.728–0.836 12.65 52.8 84.5
β-CTx (ng/L) 0.662 0.594–0.729 507 61.0 91.7
Cut-off values for the calculation of the positivity rates correspond to 95% speciﬁ-
city of the BTMS measurement in patients without BM. po0.05
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It was obvious that all BTMs were rather effective for this purpose
of differentiation. BALP was the most sensitive marker (Area under
curve(AUC): 0.78770.056). Sensitivity and speciﬁcity were cal-
culated using cut-off values that correspond to the 95% speciﬁcity
of the marker tests in the group of NSCLC patients without BM. The
cut-off values were found to be 16.96 μg/L for BALP, 52.75 ng/mL
for PINP, 12.65 ng/mL for N-MID and 507 ng/L for β-CTx.
3.3.2. ROC curves analysis of the combination of BTMs
When BTMs were combined for BM screening (Fig. 3 and
Table 4), the AUC was elevated. The most effective combination
was PINP and β-CTx, to 0.833 (95% CI, 0.785 to 0.882, po0.0001),Fig. 1. Scatterplots of bone formation markers (A, B and C) and bone resorption markers (D) in different groups of patients. Horizontal lines indicate median values. BALP,
PINP, N-MID and β-CTx values were higher in BM patients than in the control group (po0.05) and in patients without BM (po0.05). No differences were found between the
control group and the group without BM (p40.05).
Fig. 3. ROC curves for combination of BTMs to discriminate NSCLC patients with
and without BM. Area under curve for β-CTxþN-MID was 0.80270.054, for β-
CTxþPINP was 0.83370.049, for β-CTxþBALP was 0.81770.053, for N-MIDþPINP
was 0.79570.055, for N-MIDþBALP was 0.75370.059 and for PINPþBALP was
0.77770.057.
Table 4
Sensitivity, speciﬁcity, diagnostic efﬁciency of combination of BTMs to discriminate
NSCLC patients with and without BM.
Combination Area 95%CI Cut-off SE% SP%
β-CTxþN-MID 0.802 0.747–0.856 β-CTx(664)þN-MID(3.93) 63.4 89.1
β-CTxþPINP 0.833 0.785–0.882 β-CTx(584)þPINP(40.50) 61.0 91.2
β-CTxþBALP 0.817 0.765–0.870 β-CTx(508)þBALP(13.00) 64.2 90.2
N-MIDþPINP 0.795 0.740–0.850 N-MID(14.10) þPINP(45.18) 63.4 87.6
N-MIDþBALP 0.753 0.694–0.812 N-MID(8.41)þBALP(25.00) 61.8 78.8
PINPþBALP 0.777 0.721–0.834 PINP(36.00)þBALP(28.00) 68.3 78.2
po0.05
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40.5 ng/mL and β-CTx 584 ng/L (sensitivity: 61.0%, speciﬁcity: 91.2%).
3.4. Association between BTMs and clinical outcome
Table 5 shows associations between clinical outcome and all
BTMs. The demographic data for patients stratiﬁed according to
Soloway score is indicated in Table 2. There were no linearTable 5
Association Between BTMs and Clinical Data.
Characteristics BALP (μg/L) PINP (ng/mL)
The extent of BM
Soloway 1 21.31724.43n 88.917140.08n
Soloway 2 45.06741.83 177.487256.08n
Soloway 3 and 4 102.607152.73n 133.05783.71
Character of BM
Lytic 30.59750.34 108.077180.88
Blastic 24.43711.57 103.147103.97
Mixed 38.62741.63 147.087209.72
With visceral metastases
Yes 33.80754.35 130.687231.87
No 30.45735.86 101.407101.41
SREs at diagnosis
Yes 40.63778.98 122.547201.10
No 30.02733.24 99.147106.98
SREs in follow-up
Yes 54.09751.69n 180.197283.56n
No 26.64739.32 87.17797.18associations between Soloway score and the demographic char-
acteristics of patients. All BTMs indicated that linear increases with
advancing severity of the metastatic involvement of the skeletal
system. BALP, PINP and β-CTx were signiﬁcantly higher in patients
with multiple bone site involvement (Soloway 2/3 and 4) than
those with few bone site involvement (Soloway 1) (*po0.05).
No BTMs have any signiﬁcant difference among patients with
lytic, blastic or mixed bone lesions (p40.05). Neither bone for-
mation markers nor bone resorption markers differed signiﬁcantly
between patients with bone plus visceral metastases and those
with bone metastases only (p40.05). When patients with BM only
or patients with bone and visceral metastases and patients with
only visceral metastases were compared with those don't ex-
hibiting metastases, BTM were signiﬁcantly higher in the two
groups with BM with or without visceral metastases (po0.05). For
further data see Fig. 4.
During the study period, SREs occurred in 84 out of 221 pa-
tients (38.0%). 61 patients (27.6%) required bone radiation, 27 pa-
tients (12.2%) received surgery to bone, 23 patients (10.4%) with
pathologic fractures, 8 patients (3.6%) with spinal cord compres-
sion and 6 patients (2.7%) with hypercalcemia. Patients with SREs
in follow-up had higher β-CTx, BALP or PINP levels compared with
patients without SREs (po0.05), while levels did not differ sig-
niﬁcantly between patients with or without SREs at diagnosis
(p40.05).
3.5. BTMs as predictors of survival
202 of 221 patients were eligible for survival analyses. Median
followup was 15 months (range 4 to 40). The primary end point of
the analyses was NSCLC related survival. A total of 170 patients
died from NSCLC. To determine whether serum BTMs correlate
with disease outcome, patients were stratiﬁed into 2 groups by
analyte cutoff points using the 95th percentiles. To identify the
signiﬁcant prognostic factors associated with NSCLC speciﬁc death,
univariate and multivariate risk factor analyses were performed
using the Cox proportional hazards regression model in the stra-
tiﬁed groups (Table 6). BALP, ECOG, Visceral metastases and SREs
were signiﬁcant univariate predictors of death from NSCLC. These
results corresponded to Kaplan–Meier survival analysis curves.
Patients with BALP above the 95% cutoff, worse ECOG, visceral
metastases or SREs had signiﬁcant shorter survival time than pa-
tients with a lower BALP concentration, better ECOG, only bone
metastases or without SREs. However, multivariate analysis of the
signiﬁcant predictors showed that BALP, ECOG and SREs were in-
dependent predictors of NSCLC related death (Table 6). TheN-MID (ng/mL) β-CTx (ng/L) P Value
npo0.05
23.56783.5 628.847428.33n
19.01718.57 835.847897.05n
21.19711.94 1022.667725.13
p40.05
24.66782.42 695.367550.33
15.08710.27 603.157470.64
16.74710.30 758.967820.62
p40.05
21.00754.02 719.177688.68
23.64785.18 687.657524.18
p40.05
23.33781.10 719.307661.37
21.74764.67 663.907488.18
npo0.05
23.22782.36 871.707857.09n
19.71716.25 630.447465.01
Fig. 4. Scatterplots of bone formation markers (A, B and C) and bone resorption markers (D) in different groups of patients. Horizontal lines indicate median values. VS:
Visceral metastases. BALP, PINP, N-MID and β-CTx values were higher in BM patients with or without BM than in patients without BM (po0.05). No differences were found
between the BM group with or without BM, and no differences were found between the group A with or without BM.
Table 6
Cox proportional hazards regression univariate and multivariate analysis of serum
turnover markers and clinicopathological factors in 211 NSCLC patients with BM.
Variable RR 95% CI p Value
Univariate:
BALP 4.62 1.97–10.82 0.001
PINP 2.10 0.59–6.88 0.27
N-MID 1.22 0.49–3.03 0.68
CTx 1.82 0.73–4.56 0.21
ECOG 4.97 3.14-7.84 0.001
Pathologic type 1.27 0.42–3.75 0.69
Character of bone
metastases
2.48 0.87–7.29 0.12
Soloway score 2.25 0.86–5.85 0.09
Visceral metastases 4.02 1.34–11.99 0.01
SREs 11.31 2.619–48.91 0.001
Multivariate:
BALP 2.53 1.03–6.30 0.04
ECOG 3.87 2.43–6.26 0.02
Visceral metastases 2.12 0.68–6.49 0.21
SREs 7.23 1.40–33.76 0.01
Fig. 5. Kaplan–Meier curves for cancer related survival depending on BALP calcu-
lated using Kaplan–Meier method with dichotomized data using log rank test.
Criteria for dichotomous classiﬁcation were 95th percentile cutoff for BALP. The
median survival time of the patients with normal BALP was 18.0 months, sig-
niﬁcantly longer than 13.8 months in the patients with elevated BALP (po0.05).
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months, signiﬁcantly longer than 13.8 months in the patients with
elevated BALP (95%CI 12.5–15.1, po0.05) (Fig. 5). They remained
signiﬁcant variables in the forward and backward stepwise cal-
culation models.4. Discussion
Previous reports evaluating BTMs for the detection of BM in
patients with malignant diseases have concluded that urinary
N-telopeptide of type I collagen (NTx) is the most useful BTMs
[6,11,23]. The usefulness of uNTx to diagnose early BM has been
reported in several studies [24–26]. Analyses were performed in
both serum and urine, but consistent results were not alwaysdescribed. The pre-analytic variability of BTMs, their different
stability in vitro especially in urine and use of assays with different
antibodies recognizing different epitopes may explain many of the
discrepant results [28–31]. Seibel [32] indicated serum as the
preferred matrix for measurement. He reported the need to
measure formation markers (BAP, N-MID, PINP) in serum. Among
resorption markers, collagen-derived products can be measured in
serum and urine (β-CTx, NTx).
In our opinion, the preferred sample matrix is serum. The use
of a single serum for the measure of multiple markers is desirable
to simplify pre-analytical and analytical procedures. As commer-
cial assays for measuring BTMs in serum are available, we eval-
uated the diagnostic value of BTMs in clinical use in detecting BM
in NSCLC patients, BALP, PINP and OC, bone formation markers,
and CTX, bone resorption markers, which can all be measured in
Z. Wang et al. / Journal of Bone Oncology 4 (2015) 85–9190automatically in on sample are assessed. To avoid these dis-
crepancies as far as possible, we measured BTMs exclusively in
serum collected during a deﬁned time period, between 7:00 and
9:00 A.M.
The diagnosis of BM in NSCLC patients relies predominantly on
imaging techniques. Although these techniques provide useful
diagnostic tools, their use for early diagnosis or close monitoring
of patients is not without limitations. BTMs as indicators for BM in
NSCLC patients have been studied, but there are no clear re-
commendations which markers or marker combinations should be
used [7–19]. Kong [22] found that the increased CTX level had the
speciﬁcity and sensitivity of 65.6% and 68.8%, respectively, in the
diagnosis of BM in NSCLC patients, and they speculated that CTX
could be used to screen the BM of NSCLC. Ebert [7] found the
concentrations of the bone markers BALP, PINP were signiﬁcantly
higher in patients with BM than in those without BM.
In our attempt to document the predictive value of these BTMs
in NSCLC patients, we studied a cohort of 414 cancer patients with
or without radiographic evidence of BM. We measured the levels
of several BTMs in NSCLC patients to assess which BTMs, if any,
best reﬂected the presence of BM. Compared with previous lit-
eratures [12,13,15,16,34], we chose NSCLC patients with no evi-
dence of BM as the control group instead of healthy people. It is
known that the balance of bone metabolism is regulated through
the action of various systemic hormones and local mediators. We
assumed that the formation of tumor in the body, even without
evidence of BM, may inﬂuence the concentration of those hor-
mones and mediators and result in up-regulation of BTMs. Our
results showed the levels of BALP, PINP, N-MID, and β-CTX in the
BM group were signiﬁcantly higher than those in without BM
groups. The sample size is considerable and the study provides a
valid conﬁrmation of previous reports in smaller studies.
In addition to the clinical validity, both assays were un-
complicated and reliable with good analytic performance; thus,
they fulﬁlled the essential preconditions for routine measure-
ments. The PINP, N-MID and β-CTx assay was an automated assay
on a general-purpose analyzer (Elecsys). Meanwhile, BALP could
also be automated measured on an analyzer (Access, Beckman–
Colter).
Although our work has demonstrated that serum BTMs work
well in BM screening, we preferred not to deﬁne them as methods
for BM diagnosis, nor did we consider that they could replace the
screening function of imaging methods. This is because BM is a
complicated process, and serum BTMs of an individual patient may
be inﬂuenced by unknown elements. Serum markers are also
unable to fulﬁll some functions of imaging methods, such as lo-
calizing the bone metabolic abnormality.
In our study, the levels of BALP, PINP and β-CTx in the serum
were signiﬁcantly (po0.05) correlated with the number of ske-
letal sites involved with metastases, but there was no signiﬁcant
difference in the levels of BTMs among patients with olytic lesions,
blastic lesions and mixed lesions. A possible explanation to these
ﬁndings could be that tumors may secrete these bone regulatory
proteins regardless of their location, thus circulating levels maybe
elevated even when skeletal involvement has not emerged. His-
tomorphological results show that osteolytic and osteoblastic
metastases are characterized by simultaneous resorptive and os-
teoblastic processes [6]. The simultaneous increases of bone for-
mation markers and bone absorption markers indicate that the
bone formation and bone absorption occur at the same time in
patients with BM.
One feature of our research was that we chose two BTMs and
combined them for analysis. As the univariate evaluation of data
showed dissociated changes of serum marker concentrations for
both bone formation and resorptions, multivariate analysis was
appropriate. Logistic regression analysis of all variables showedthat the combination of β-CTx and PINP was the best way to dif-
ferentiate between BM and nonmetastases. We assumed that si-
multaneous elevation of the two BTMs could represent a more
robust judgement for BM. Our data was consistent with this as-
sumption: when the bone formation markers and bone resorption
markers were used together, the sensitivity and speciﬁcity for BM
screening were improved as compared with the BTMs being used
separately.
Another feature of our research was that we used BTMs clini-
cally to predict the risk of SREs. We found that if patients had a
higher β-CTx, BALP or PINP levels at baseline, they were at a higer
risk of SREs. A similar pattern was seen in an study [3] evaluating
NTx and BALP levels for 441 patients on the placebo arms of the
previously noted clinical trials of zoledronic acid in patients with
BM from prostate cancer, NSCLC and other solid tumors. Patients
with high NTx or BALP levels had a greater incidence of SREs
compared with patients with low levels of NTx or BALP. Because
survival after diagnosis of BM is relatively short for patients with
NSCLC, methods are needed to predict SREs in a shorter timescale
than it is possible with current imaging methods. From the results
of our current study, the use of BTMs at baseline may make a
major contribution to this need by identifying those patients at
highest risk who warrant the highest priority for intervention to
prevent SREs.
In our study, we evaluated the relationship between serum
BTM levels and overall survival (OS) in NSCLC. Correlation analysis
revealed that BALP was related to the survival time. Regression
analysis showed the number of BM sites, the characteristics of BM
(lytic, blastic or mixed), sex and Soloway score did not signiﬁcantly
affect the survival time. When considering the 4 markers that we
studied, BALP was the only signiﬁcant univariate predictor of
death from NSCLC. Patients with low serum BALP tend to have
longer survival than those with high BALP. The prognostic sig-
niﬁcance of BALP was veriﬁed by multivariate Cox regression
analysis since BALP, ECOG and SREs were independent factors of
cancer related death. Thus, BALP really appeared to be more a
marker of tumor burden or activity than a simple indicator of bone
turnover. In addition, the association of BALP with the survival of
NSCLC patients could be used for stratifying patients with ad-
vanced NSCLC for clinical trials in the current treatment options
with bisphosphonates or other chemotherapeutic agents to in-
dividualize treatment. For patients with NSCLC, although this
analysis cannot address the possibility of a causal link between
increases in BTMs and OS, it does suggest that higher BTMs at
baseline could have a negative effect on disease progression and
might worsen survival.
Some studies assessing the relationship between urinary NTx
level and OS in NSCLC have shown that high urinary NTx levels are
associated with an increased risk of death [26,35,36]. Further, re-
cent studies have suggested that zoledronic acid and denosumab
reduce baseline urinary NTx level [25,36]. Moreover, patients with
NSCLC and high baseline NTx levels that were normalized after
chemotherapy including zoledronic acid were found to experience
longer survival compared with patients whose NTx levels re-
mained persistently high [6,36,37]. These study inspired us to ﬁnd
the relation between the change of BTMs and OS. The results of a
randomized prospective study would be more credible, and that is
what we want to do in the future. But our ﬁnding that baseline
BTMs levels were predictive of death is also important because it
can be argued that baseline BTMs assessments allow more time for
appropriate intervention.
5. Conclusion
Our results suggest that, despite of the limitations, measure-
ment of serum BTMs concentration is a powerful test alone or in
Z. Wang et al. / Journal of Bone Oncology 4 (2015) 85–91 91combination with other BTMs to detect BM and to predict SREs
and survival probability in NSCLC patients. However, to fully es-
tablish the role of BTMs in clinical practice, prospective studies are
needed. Now our suggestion for the proper application of serum
BTMs in BM screening is as follows: serum BTMs should be eval-
uated at once since a patient is diagnosed NSCLC to establish his/
her baseline values, and then be monitored regularly and com-
pared with his/her previous results. If the baseline values are
higher than the cut-off value, or if abnormal variation is found
during the follow up, imaging methods should be applied for
further conﬁrmation. If necessary, appropriate intervention should
be taken as soon as possible. If the serum BTMs would be used this
way, BM screening could become more timely and accurate. As a
result, meaningful improvements of life quality and treatment to
NSCLC patients may be achieved.Conﬂict of interest
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